Owen Mumford appoints new director of research and development
WOODSTOCK – OXFORDSHIRE, England, June 8, 2022 – Owen Mumford, a global leader in the design, manufacturing, and development of medical devices, today announced it has appointed Bal Johal as director of research and development, effective July 4, 2022.
Johal brings extensive experience in the pharmaceutical and medical device industries, spanning multiple therapeutic areas and dosage formats. Most recently, she served as vice president of product development, quality, regulatory, and medical at Circassia. Before that, she held positions in research and development at GlaxoSmithKline, Pfizer, and Mundipharma Research Ltd.
Research and development have always been central to Owen Mumford’s unique offering and serve as a key pillar of the company’s strategic goals and growth. Appointing Johal to this key role will strengthen and improve the company’s current pipeline. It also ensures a clear path to deliver new ambitions in innovation, sustainable product design, life-cycle assessments, and greater positive impacts on the experiences of healthcare professionals and patients.
“We are very pleased to welcome Bal to our company,” said Jarl Severn, managing director at Owen Mumford. “She brings the background, expertise, and energy to keep driving the innovation and forward-thinking that will allow us to achieve ambitious growth and distinguish ourselves from the competition.”
Reflecting on her appointment, Johal said, “Joining Owen Mumford at this time is incredibly exciting. With the progress already made and a team of very talented people, I am confident we will achieve high standards of success and innovation with a truly positive impact.”